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Abstract
Background: Differences in the genetic architecture of inflammatory bowel disease between different European
countries and ethnicities have previously been reported. In the present study, we wanted to assess the role of 11
newly identified UC risk variants, derived from a recent European UC genome wide association study (GWAS)
(Franke et al., 2010), for 1) association with UC in the Nordic countries, 2) for population heterogeneity between
the Nordic countries and the rest of Europe, and, 3) eventually, to drive some of the previous findings towards
overall genome-wide significance.
Methods: Eleven SNPs were replicated in a Danish sample consisting of 560 UC patients and 796 controls and
nine missing SNPs of the German GWAS study were successfully genotyped in the Baltic sample comprising 441
UC cases and 1156 controls. The independent replication data was then jointly analysed with the original data and
systematic comparisons of the findings between ethnicities were made. Pearson’s c
2, Breslow-Day (BD) and
Cochran-Mantel-Haenszel (CMH) tests were used for association analyses and heterogeneity testing.
Results: The rs5771069 (IL17REL) SNP was not associated with UC in the Danish panel. The rs5771069 (IL17REL) SNP
was significantly associated with UC in the combined Baltic, Danish and Norwegian UC study sample driven by the
Norwegian panel (OR = 0.89, 95% CI: 0.79-0.98, P = 0.02). No association was found between rs7809799 (SMURF1/
KPNA7) and UC (OR = 1.20, 95% CI: 0.95-1.52, P = 0.10) or between UC and all other remaining SNPs. We had 94%
chance of detecting an association for rs7809799 (SMURF1/KPNA7) in the combined replication sample, whereas the
power were 55% or lower for the remaining SNPs.
Statistically significant PBD was found for OR heterogeneity between the combined Baltic, Danish, and Norwegian
panel versus the combined German, British, Belgian, and Greek panel (rs7520292 (P = 0.001), rs12518307 (P =
0.007), and rs2395609 (TCP11) (P = 0.01), respectively).
No SNP reached genome-wide significance in the combined analyses of all the panels.
Conclusions: This replication study supports an important role for the studied rs5771069 (IL17REL) SNP, but not for
rs7809799 (SMURF1/KPNA7), in UC etiology in the Danish, Baltic, and Norwegian populations. Significant genetic
heterogeneity was suggested for rs7520292, rs12518307, and rs2395609 (TCP11) in UC etiology between the Nordic
and the other European populations.
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The chronic inflammatory bowel diseases (IBD), ulcera-
tive colitis (UC) and Crohn’s disease (CD), are complex
diseases caused by an interplay between genetic and
environmental factors [1]. The recent years have
brought much progress regarding the genetic etiology of
IBD [1-15] and the number of confirmed IBD associated
loci has risen to more than 99 confirmed associations
[5,10-17], with more than 28 shared CD/UC risk loci.
For a detailed review of the genetic findings and the
genetic overlap with other inflammatory diseases see
Lees et al. [18].
Studies have found that disease distribution and phe-
notypic appearance differ significantly between ethnic
groups and even within populations [19-21] although
other studies disagree [22]. Thus, uneven geographic
distribution of IBD has been found within European
countries such as Scotland [23] and France [24], and
also within the USA [25]. Apart from varying environ-
mental factors that affect susceptible individuals, genetic
heterogeneity between different populations itself plays
an important role.
Emerging evidence suggests that the contribution from
each gene to IBD development may vary considerably
among different populations. Heterogeneity has been
found for IBD risk candidate genes such as COX-2 [26]
and ABCB1 (MDR1) [27-29] gene variants. Also the
CD-associated NOD2 variants have demonstrated a
remarkable amount of heterogeneity across ethnicities
and populations [30,31]. Case control studies have
found that the contribution to IBD disease susceptibility
of the NOD2 variants is low in the non-Caucasian popu-
lation [32-34] and, furthermore, in the Swedish, Norwe-
gian, Baltic, and Danish populations [12,35-41]. In spite
of this, a meta-analyses found no difference between the
impact of the CD-associated NOD2v a r i a n t si nt h e
Northern and Southern European populations, which
may be due to the methodological reason as e.g. the
German panel was included in the Northern European
populations [42]. Thus, the Nordic populations may
have a distinct pattern of IBD risk-associated gene var-
iants compared to Central European countries. It is
therefore of particular interest to search for genetic
determinants in these populations which are charac-
terised by few identified susceptibility genes.
In the present study, we wanted to assess the role of
11 newly identified UC risk variants, derived from a
recent European UC genome wide association study
(GWAS), for association with UC in the Nordic coun-
tries [7]. In the specific GWAS, Franke and colleagues
identified 11 SNPs which were subsequently replicated
in an independent sample set [7]. Furthermore, we
wanted to evaluate these 11 SNPs for population
heterogeneity between the Nordic countries and the rest
o fE u r o p e ,a n d ,e v e n t u a l l y ,w ew a n t e dt od r i v et h ep r e -
vious findings towards overall genome-wide significance.
We genotyped all 11 SNPs in a Danish UC case-control
sample and 9 SNPs, which were previously not tested in
the respective panel, were genotyped in a Baltic UC
case-control sample. Furthermore, we included the pre-
viously published data on the 2 SNPs, rs7809799 and
rs5771069, from the Baltic sample and on all 11 SNPs
from the Norwegian, Belgian, British, German and
Greek sample from the primary GWAS study in the
analyses [7]. In total, we analysed 3097 cases and 6223
controls from the Baltic, Danish and Norwegian samples
(1275 cases and 2234 controls) and the Belgian, British,
German and Greek panels (1822 cases and 3989
controls).
Methods
Patients and controls
The Baltic study population consisted of 441 UC
patients and 1156 controls recruited at 6 hospitals in
Lithuania (401 cases and 1099 controls) and 2 hospitals
in Latvia (40 cases and 57 controls) [7]. The Danish
study population consisted of 560 UC patients and 796
healthy blood donors recruited at 3 hospitals in the
Northern part of Jutland [15]. All study participants
were of Caucasian ethnicity based on self-reported infor-
mation. Diagnosis of UC was based on standard clinical,
radiological, endoscopic and histological criteria [43].
Selection of single nucleotide polymorphisms
The 11 SNPs of the formerly published GWAS were
selected because they were reported as robust replica-
tions [7] leaving out SNPs that were found to have sig-
nificantly different allele frequencies when comparing
the different countries (PBC < 0.05; P-value for Breslow
day test), or which were previously replicated as UC-
associated variants [7]. Thus, 11 SNPs were selected:
rs7520292, rs1488266 (BTLA), rs3103190, rs12518307,
rs2395609 (TCP11), rs7809799 (SMURF1/KPNA7),
rs6966125 (TNPO3), rs638300, rs6119625 (FER1L4),
rs6125345, and rs5771069 (IL17REL). Genotype data on
all 11 SNPs in the Norwegian, Belgian, British, German
and Greek panels was derived from the original GWAS
replication study and included in further analyses.
Rs5771069 and rs7809799 in the Baltic panel had been
genotyped in the origininal GWAS replication study.
The depletion of DNA stocks required an exchange of
some samples used in the original analysis, however, the
sampleset used for this analysis here is >98% concordant
to the one used in the Franke et al paper. For not intro-
ducing a bias by using experimental data for the 2 pre-
viously typed SNPs we also typed these 2 SNPs again.
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Baltic cohort.
Genotyping
Functionally tested TaqMan
® SNP Genotyping Assays
(Applied Biosystems, Foster City, USA) were used to
genotype the 11 SNPs in the Danish sampleset and the
9 SNPs missing in the Baltic [44]. SNPlex were used for
the Belgian, British, German and Greek panels and the
Affymetrix Genome-Wide Human SNP Array 5.0 for
the Norwegian sample set as previously described [7].
All process data were written to and administered by a
previously described database-driven laboratory informa-
tion management system (LIMS) [45]. Duplicate or
related samples were identified and excluded from the
analyses, using algorithms implemented in the LIMS.
However, no specific genotyping was conducted to “ID”
tag the DNA samples. HapMap controls with known
genotypes were included in each run, and repeated gen-
otyping of a random 10% subset yielded 100% identical
genotypes. Genotypes were obtained for less than 95%
of the Danish study group only for SNP rs6125345 and
excluded from further analyses. The genotype distribu-
tions among the controls did not deviate from Hardy-
Weinberg equilibrium (PHWE < 0.05) in either of the
study populations.
Association analyses
Genotype data from the present study and from pre-
existing GWAS on rs5771069 and rs7809799 from the
Baltic cohort and on all the 11 SNPs from the Norwe-
gian, Belgian, British, German and Greek cohorts [7]
were analysed using gPLINK v2.050 in combination
with PLINK v1.07 [46]. Pearson’s c
2 test on allele
counts (PCCA; 1 degree of freedom) was used for the
separate analyses of the Baltic and Danish cohorts. The
asymptomatic P-value of the Breslow-Day (PBD)t e s t
was used for analysing the heterogeneity of the odds
ratios (ORs). The Cochran-Mantel-Haenszel (CMH)
test was used for statistic analyses of the combined P-
values (PCMH) and combined odds ratios. We used the
tool “Confidence Interval of differences and Forest
Plots” and Microsoft Office Excel 2007 for forest plot
analyses [47].
Power analyses
We used the tool “Genetic Power Calculator” [46] for
power analyses. The minor allele frequencies in the con-
trol group and ORs were retrieved from Franke et al [7]
a n du s e df o r“high risk allele frequency” and “genotype
relative risk”, respectively, the “prevalence” was set to
0.001, D-prime was set to 1, number of cases was 1275
and control:case ratio 0.9. Type I error rate = 0.05, user-
defined power (1-type II error rate) = 0.80.
Ethical Considerations
The study was conducted in accordance with the
Declaration of Helsinki. Written, informed consent was
obtained from all study participants. All protocols were
approved by the national and institutional ethical review
committees of the participating centres (Lithuania 2/
2008, Latvia 290910-8L) or local Scientific Ethical Com-
mittees (Denmark) (VN 2003/5 and VN 2003/124).
Results
Detailed characteristics of the Baltic, Danish and Norwe-
gian IBD patients and controls are shown in Table 1. A
total of 1275 cases and 2234 controls were included in
the analyses.
Analyses for SNP associations in the separate Baltic,
Danish, and Norwegian case-control panels
Table 2 shows the allele frequencies, association results
and ORs of the 11 SNPs for the separate Baltic, Danish,
and Norwegian case-control panels. A P-value of less
than 0.05 was considered as statistically significant as all
variants are independent from each other and previously
described as true associations, i.e. no correction for mul-
tiple testing was applied. Rs12518307 was associated
with risk of UC in the Danish cohort at the 5% level (p
< 0.05). As previously reported by Franke et al. (table S-
five) [7] rs7809799 was associated with risk of UC in the
Baltic cohort, and rs5771069 with risk of UC in the
Norwegian cohort (IL17REL). The allele frequencies for
the 11 SNPs in the combined German, British, Belgian,
and Greek panel are shown for comparison reasons
(Table 2).
Analyses for SNP associations in the combined Baltic,
Danish, and Norwegian panel
Table 3 shows OR for the 11 SNPs and risk of UC for
the combined Baltic, Danish and Norwegian panel ver-
sus the combined German, British, Belgian, and Greek
panel. Figure 1 and 2 shows the OR for rs7809799
(SMURF1/KPNA7) and rs5771069 (IL17REL)f o rt h e
individual panels and combined panels, respectively.
The rs5771069 (IL17REL) SNP is statistically signifi-
cantly associated with UC in the combined Northern
European sample set (OR = 0.89, 95% CI: 0.79-0.98, P
= 0.02). Figure 2 and the PCCA values show that this
association was mainly based on the Norwegian panel
as has previously been reported by Franke et al [7]. In
the study by Franke et al [7] the rs5771069 G allele is
denoted as the A1 allele, whereas in this study the
rs5771069 A allele is denoted as the A1 allele. No
association between rs7809799 (SMURF1/KPNA7) and
UC was observed (OR = 1.20, 95% CI: 0.95-1.52, P =
0.10; the ap r i o r iestimated chance of detection was
94%). No other association between any of the studied
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European panel. The estimated power of the combined
Baltic, Danish and Norwegian panel to detect a possi-
ble association at the a = 0.05 significance level,
assuming a variant allele frequency similar to what was
observed in the study by Franke et al.[ 7 ]( o n l yd a t a
from replication panel used, i.e. inflated GWAS data
excluded), is shown in Table 3. The power to detect a
real association was 94% for the rs7809799 (SMURF1/
KPNA7), whereas the power was 55% or lower for the
remaining SNPs.
Breslow-Day significance tests for odds ratio heteroge-
neity (PBD) between the panels in the combined analyses
did not reach statistical significance for any of the SNPs
(Table 3).
Analyses for heterogeneity between the combined Baltic,
Danish, and Norwegian panel and the combined German,
British, Belgian, and Greek panel
The result of the analyses for OR heterogeneity between
the combined Baltic, Danish, and Norwegian panel ver-
sus the combined German, British, Belgian, and Greek
panel is shown in Table 3. Statistically significant PBD
was found for 3 SNPs; the rs7520292 (P = 0.001),
rs12518307 (P = 0.007), and rs2395609 (TCP11)( P=
0.01), respectively. For comparison, table 3 shows the
Table 1 Participant description
Baltic Danish Norwegian
cases controls cases controls cases Controls
N = 441 N = 1156 N = 560 N = 796 N = 274 N = 282
Sex distribution
% female 50 51 48 52 48 41
Age at sampling
Median age (years, SD) 44 [17] 40 [12] 49 [16] 43 [11] 39 [15] 32 [7]
Age of diagnosis
Median age (years, SD) 38 [16] 35 [11] 38 [15]
Disease extent, %
Left sided colitis 76 80 69
Extensive colitis 24 20 31
Smoking habits, %
Current 12 17 13
previous 28 36 31
never 60 47 56
In all three panels age- and sex-matched controls have been used.
Table 2 Odds ratios (OR) for the 11 SNPs for the Baltic, Danish and Norwegian UC panels
1
Baltic
1
441 UC cases/1156 controls
Danish
560 UC cases/796 controls
Norwegian
1
274 UC cases/282 controls
European
1
3989 co/
1822 ca
SNP A1 FCA FCO OR 95% CI PCCA FCA FCO OR 95% CI PCCA FCA FCO OR 95% CI PCCA FCA
rs7520292 A 0.20 0.20 1.04 0.85-1.25 0.71 0.17 0.16 1.01 0.81-1.24 0.94 0.16 0.16 1.00 0.73-1.38 0.96 0.20
rs1488266 BTLA C 0.06 0.06 0.95 0.69-1.29 0.72 0.10 0.11 0.91 0.71-1.16 0.45 0.09 0.10 0.90 0.60-1.36 0.64 0.10
rs3103190 G 0.40 0.41 0.98 0.83-1.14 0.76 0.30 0.33 0.87 0.73-1.02 0.09 0.31 0.31 0.99 0.77-1.27 0.95 0.34
rs12518307 A 0.33 0.33 1.00 0.84-1.17 0.99 0.27 0.23 1.19 1.00-1.42 0.04 0.27 0.26 1.04 0.79-1.35 0.77 0.25
rs2395609 TCP11 G 0.29 0.30 0.92 0.77-1.09 0.35 0.34 0.33 1.04 0.88-1.23 0.60 0.35 0.36 0.97 0.76-1.24 0.83 0.32
rs7809799 SMURF1/
KPNA71
G 0.07 0.05 1.42 1.03-1.94 0.03 0.03 0.04 0.86 0.57-1.27 0.44 0.04 0.02 1.6 0.86-3.23 0.11 0.05
rs6966125 TNP03 G 0.21 0.20 1.01 0.83-1.22 0.89 0.15 0.14 1.10 0.88-1.36 0.40 0.12 0.14 0.84 0.59-1.19 0.33 0.16
rs638300 T 0.15 0.14 1.09 0.88-1.35 0.42 0.20 0.20 0.97 0.80-1.17 0.77 0.21 0.19 1.10 0.82-1.48 0.49 0.21
rs6119625 FER1L4 G 0.15 0.14 1.08 0.87-1.34 0.47 0.13 0.12 1.11 0.88-1.39 0.37 0.13 0.10 1.28 0.89-1.83 0.17 0.15
rs6125345 C 0.17 0.18 0.93 0.75-1.13 0.45 0.19 0.16 1.20 0.88-1.63 0.24 0.20
rs5771069 IL17REL A 0.50 0.52 0.93 0.79-1.08 0.31 0.49 0.50 0.97 0.82-1.12 0.67 0.43 0.53 0.69 0.54-0.87 0.002 0.49
1Data for the 11 SNPs in the Norwegian panel, for rs5771069 and rs7809799 in the Baltic panel, and the allele frequencies for the combined German, British,
Belgian, and Greek panel is from Franke et al [7].
A1: minor allele; F: allele frequency of A1 for cases (FCA) or controls (FCO), respectively; 95%CI: 95% confidence interval; PCCA: P-value (Pearson’s c
2 test on allele
counts with one degree of freedom); nominal significant P-values are highlighted by bold type
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Page 4 of 9Table 3 Odds ratios (OR) for the combined UC panels and heterogeneity test for the Northern countries (Baltic,
Norwegian, and Danish) versus rest of Europe (German, British, Belgian, and Greek)
Baltic, Norwegian, and
Danish
1
1275 cases and 2234
controls
German, British, Belgian, and
Greek
1
1822 cases and 3989 controls
Northern vs rest
of Europe
Baltic, Norwegian,
Danish, German, British,
Belgian, and Greek
3097 cases/6223 controls
SNP A1 PBD ORCMH 95%CI PCMH Power PBD ORCMH 95%CI PCMH PBD ORCMH 95%CI PCMH
rs7520292 A 0.98 1.02 0.89-1.16 0.75 43% 0.13 1.19 1.08-1.32 0.004 0.001 1.13 1.04-1.22 0.003
rs1488266 BTLA C 0.98 0.92 0.77-1.09 0.35 49% 0.50 0.83 0.72-0.95 0.01 0.14 0.87 0.78-0.97 0.01
rs3103190 G 0.54 0.93 0.84-1.03 0.20 30% 0.06 0.86 0.79-0.94 0.001 0.71 0.89 0.84-0.96 0.001
rs12518307 A 0.34 1.07 0.96-1.20 0.18 39% 0.17 0.86 0.78-0.95 0.002 0.007 0.95 0.88-1.02 0.16
rs2395609 TCP11 G 0.59 0.98 0.88-1.09 0.73 39% 0.17 0.84 0.77-0.92 0.0002 0.01 0.90 0.84-0.96 0.002
rs7809799
SMURF1/KPNA71
G 0.09 1.20 0.95-1.52 0.10 94% 0.81 1.43 1.19-1.71 0.0001 0.10 1.34 1.16-1.55 0.00005
rs6966125 TNP03 G 0.45 1.01 0.88-1.16 0.82 54% 0.34 0.83 0.73-0.93 0.001 0.12 0.90 0.83-0.99 0.02
rs638300 T 0.65 1.03 0.91-1.18 0.55 55% 0.10 1.19 1.08-1.31 0.0003 0.18 1.14 1.05-1.23 0.001
rs6119625 FER1L4 G 0.72 1.12 0.97-1.29 0.11 47% 0.90 1.19 1.06-1.33 0.001 0.29 1.17 1.07-1.28 0.0006
rs6125345 C 0.33 1.03 0.90-1.18 0.64 39% 0.45 1.15 1.03-1.27 0.006 0.29 1.11 1.02-1.20 0.01
rs5771069 IL17REL A 0.06 0.89 0.79-0.98 0.02 29% 0.54 0.89 0.82-0.97 0.008 0.86 0.89 0.84-0.95 0.0005
1Data on the 11 SNPs in the Norwegian, German, British, Belgian, and Greek cohort, and on rs5771069 and rs7809799 in the Baltic cohort is derived from the
study of Franke et al [7]. In the study by Franke et al [7] the rs5771069 G allele is denoted as the A1 allele, whereas in this study the rs5771069 A allele is
denoted as the A1 allele. Combined P-values (PCMH) and combined ORs (ORCMH) of the Cochran-Mantel-Haenszel (CMH) test statistic; Breslow-Day test for odds
ratio heterogeneity between countries (PBD); A1: minor allele in healthy controls; F: allele frequency of A1 for cases (FCA) and controls (FCO), respectively; 95%CI:
95% confidence interval; nominal significant P-values are highlighted by bold type;
rs12518307
Baltic
Danish
Norwegian
German
British
Belgian
01 1 0
Greek
German GWAS
Combined Franke et al
Combined all
Combined Nordic
Combined other European
Figure 1 Detailed analyses of rs12518307.
1Data for for Norwegian, German, British, Belgian, and Greek panel, and the original German GWAS
is from Franke et al [7]; Combined Franke et al = Norwegian, German, British, Belgian, and Greek panel; Combined all = Baltic, Danish,
Norwegian, German, British, Belgian, and Greek panel; Combined Nordic = Baltic, Danish, and Norwegian panel; Combined other European =
German, British, Belgian, and Greek panel; nominal significant P-values are highlighted by blue.
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ginal GWAS study including data from the other Eur-
opean panels; i.e. the German, British, Belgian, and
Greek sample sets (1822 cases and 3989 controls) (pre-
viously published in Supplementary Table S-four in [7]).
Figure 3 shows the OR for rs12518307 for the individual
panels and combined panels.
Analyses for SNP associations in the combined Baltic,
Danish, Norwegian, German, British, Belgian, and Greek
panel
Table 3 shows OR for the 11 SNPs and risk of UC for
the combined Baltic, Danis h ,N o r w e g i a n ,G e r m a n ,
British, Belgian, and Greek panel, including 3097
cases and 6223 controls. No association between any
of the studied SNPs and UC on genome-wide signifi-
cance level (P < 5 × 10
-8) was identified in the com-
bined panel.
Discussion
The present case-control study assessed the association
with UC in Northern European panels, comprising 1275
patients and 2234 controls from Denmark, Norway,
Lithuania and Latvia, for 11 recently identified SNPs [7].
In the combined analyses of the three panels, rs5771069
(IL17REL), but not rs7809799 (SMURF1/KPNA7), was
statistically significantly associated with UC. Statistically
significant heterogeneity between the combined panel
from the three Nordic countries versus the other Eur-
opean panels was found for three SNPs (rs7520292,
rs12518307, and rs2395609 (TCP11)). No SNP reached
genome-wide significance in the combined analyses of
all the panels.
Although this study found significant association in
the combined Northern European panels between UC
and rs5771069 (IL17REL), rs5771069 did not show asso-
ciation in the Baltic (data from [7]) or Danish panel.
Thus, this result was based on the Norwegian sample
(data from [7]). Next, we were not able to replicate the
association with rs7809799 (SMURF1/KPNA71) in spite
of sufficient power which suggests that this SNP does
not contribute to UC etiology in these countries. The
associations found in the separate analyses of the three
Northern European sample sets may be due to chance
and therefore needs replication in other samples to be
verified. It is important to stress the strengths and
Baltic
Danish
Norwegian
German
British
Belgian
Rs7809799 SMURF1/KPNA71
0,10 1,00 10,00
g
Greek
German GWAS
Combined Franke et al
Combined all
Combined Nordic
Combined other European
Figure 2 Detailed analyses of rs7809799 SMURF1/KPNA71.
1Data for rs7809799 in the Baltic panel, and for Norwegian, German, British,
Belgian, and Greek panel, and the original German GWAS is from Franke et al [7]; Combined Franke et al = Norwegian, German, British, Belgian,
and Greek panel; Combined all = Baltic, Danish, Norwegian, German, British, Belgian, and Greek panel; Combined Nordic = Baltic, Danish, and
Norwegian panel; Combined other European = German, British, Belgian, and Greek panel; nominal significant P-values are highlighted by blue.
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a single, independent hypothesis test, allowing for a nom-
inal significance threshold. The associations, in general,
did not withstand Bonferroni correction for multiple test-
ing with a significant P-value of 0.05/11 SNP tested =
0.0045. However, Bonferroni correction may be overly
conservative in our setting where we aimed to replicate
previously identified risk variants [48]. Although this
study had 94% power to detect a real association between
rs7809799 (SMURF1/KPNA71) and UC in the combined
Baltic, Danish, and Norwegian study sample if there was
one, the power to detect an association with e.g.
rs5771069 (IL17REL) was low. Therefore, further recruit-
ment efforts are essential to increase the Northern Eur-
opean study sample size for validating the importance of
the yet established susceptibility loci.
Next, our study suggests genetic heterogeneity
between the Northern and the rest of the European
populations. The Breslow-Day test for odds ratio hetero-
geneity was significant for rs7520292, rs12518307, and
rs2395609 (TCP11) between the combined Baltic, Dan-
ish, and Norwegian sample and the combined German,
British, Belgian, and Greek sample (Table 3). Interest-
ingly, also within the Northern countries 2 SNPs
pointed to a certain amount of population stratification.
Although not statistically significant, the Breslow-Day
test found values of 0.06 and 0.09 for rs7809799
(SMURF1/KPNA71) and rs5771069 (IL17REL), respec-
tively. Varying environmental exposure between coun-
tries for factors that affect susceptible individuals may
contribute to these findings, i.e. environmental expo-
sures such as tobacco smoking and diet [49,50] may
rs5771069 IL17REL
Baltic
Danish
Norwegian
German
British
Belgian
0,10 1,00 10,00
Belgian
Greek
German GWAS
Combined Franke et al
Combined all
Combined Nordic
Combined other European
Figure 3 Detailed analyses of and rs5771069 IL17REL.
1Data for rs5771069 in the Baltic panel, and for Norwegian, German, British, Belgian,
and Greek panel, and the original German GWAS is from Franke et al [7]; Combined Franke et al = Norwegian, German, British, Belgian, and
Greek panel; Combined all = Baltic, Danish, Norwegian, German, British, Belgian, and Greek panel; Combined Nordic = Baltic, Danish, and
Norwegian panel; Combined other European = German, British, Belgian, and Greek panel; nominal significant P-values are highlighted by blue.
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t h er i s ko fI B D .T h e r e b y ,d i fferences in environmental
risk factors between countries may contribute to differ-
ences in the identified risk genes. Thus, genetic hetero-
geneity between the different populations in
combination with varying environmental exposure
impedes the detection of real associations, preferring
carefully selected combinations of different panels.
Investigating the detailed structure of the Baltic coun-
tries and other North-Eastern European populations,
revealed that the Baltic countries Poland and Western
Russia together form a genetic cluster [51], thereby indi-
cating that the two Baltic study populations can be com-
bined in association analyses. Eventually, population-
based genotyping and estimation of the penetrance of
disease susceptibility genes in different populations will
teach us about the impact of the genetic heterogeneity
[36].
Finally, no SNP were found to be associated with UC
at a genome-wide level in the analyses of all panels
combined.
In summary, our study suggest that rs5771069
(IL17REL) is a genetic susceptibility factor in Northern
European countries [7], whereas we failed to replicate
the association of rs7809799 with UC in the present
adequately-powered study. The data suggest significant
heterogeneity for rs7520292, rs12518307, and rs2395609
(TCP11) between the Northern and the rest of the Eur-
opean populations. Eventually, we were not able to
reach genome-wide association level of any of the inves-
tigated SNPs with UC.
Conclusions
This study supports an important role for the studied
rs5771069 (IL17REL) SNP, but not for rs7809799
(SMURF1/KPNA7), in UC etiology in the Northern Eur-
opean population. Significant genetic heterogeneity was
suggested for rs7520292, rs12518307, and rs2395609
(TCP11) in UC etiology between the Northern and the
rest of the European populations.
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